CSL (ASX:CSL) Alentis Deal Puts Its Undervalued Narrative Back In Focus

CSL (ASX:CSL) has moved into sharper focus after agreeing to an exclusive global alliance with Alentis Therapeutics to co-develop lixudebart, a claudin-1 targeted drug for rare kidney and liver conditions.

The recent collaboration headlines arrive after a sharp 90-day share price return of 51.4% and a 30-day share price gain of 7.6% from around A$171 to A$184.59. However, the 1-year total shareholder return is still down 12.5% and the 5-year total shareholder return is down 32.6%, suggesting that short-term momentum in CSL is picking up while longer term holders remain under water.

See how CSL compares to other rare disease and healthcare leaders by reviewing our curated list of list of solid balance sheet and fundamentals (12 results).

CSL now trades only a fraction below the latest analyst price target after a sharp rebound. Does the current setup still skew the risk and reward toward buyers, or has most of the upside been pulled forward already?

Most Popular Narrative: 12.1% Undervalued

Against the latest narrative fair value of A$210, CSL trading at A$184.59 implies a meaningful gap that the market has not closed, even after the recent rally.

CSL is one of Australia’s highest-quality businesses and has a long history of delivering strong returns. It is a global leader in plasma therapies, vaccines and biotechnology, with products that are difficult to replicate and protected by strict regulation.

See why 41 investors see CSL as 12% undervalued.

Result: Fair Value of A$210 (UNDERVALUED)

Still, CSL’s narrative can be challenged if new therapies underwhelm regulators or if currency swings and integration issues at Vifor affect reported results.

Find out about the key risks to this CSL narrative.

Next Steps

The mix of optimism and caution around CSL only matters if you test it against the numbers yourself. You can then decide where you stand using the 3 key rewards and 1 important warning sign.

Looking for more CSL-sized opportunities?

If CSL has sharpened your focus on quality, do not stop there. Use powerful screeners to surface fresh ideas before they move without you.

• Target value by zeroing in on companies that combine solid fundamentals with appealing pricing through the 4 high quality undervalued stocks.
• Prioritise resilience by scanning for businesses with sturdier finances using the 6 resilient stocks with low risk scores.
• Get ahead of the crowd by reviewing a focused 15 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com